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a b s t r a c t
Vaccinia virus (VACV) is a large double-stranded DNA virus with a complex cytoplasmic replication cycle
that exploits numerous cellular proteins. This work characterises the role of a proviral cellular protein,
the small GTPase RAB1A, in VACV replication. Using siRNA, we identiﬁed RAB1A as required for the
production of extracellular enveloped virions (EEVs), but not intracellular mature virions (IMVs).
Immunoﬂuorescence and electron microscopy further reﬁned the role of RAB1A as facilitating the
wrapping of IMVs to become intracellular enveloped virions (IEVs). This is consistent with the known
function of RAB1A in maintenance of ER to Golgi transport. VACV can therefore be added to the growing
list of viruses which require RAB1A for optimal replication, highlighting this protein as a broadly proviral
host factor.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
Vaccinia virus (VACV) is the prototypic virus of the Orthopoxvirus
genus of Poxviridae, a family of large, double stranded DNA viruses
which undertake a complex replication cycle entirely within the
cytoplasm of an infected cell. Multiple forms of the poxvirus virion
are produced during the cycle, and can be differentiated by their
cellular location, number of membranes, abundance and function.
After entering a cell, via plasma membrane fusion or endocytosis, the
VACV virion travels to a perinuclear location to establish a cytoplas-
mic viral factory (Moss, 2007). These factories produce abundant
numbers of intracellular mature virus (IMV), which consists of a core
particle surrounded by a single lipid membrane that is embedded
with entirely nonglycosylated viral proteins. A small fraction of IMVs
(approximately 1% (Payne, 1980)) exit the viral factory and are
wrapped by two additional cellular membranes that are embedded
with glycosylated viral proteins to form intracellular enveloped
virions (IEVs) (Hiller and Weber, 1985). IEVs then travel to the
periphery of the cell where their outermost membrane fuses with
the plasma membrane, leaving a cell associated virion (CEV)
surrounded by the two remaining membranes. CEVs released from
the surface are known as extracellular enveloped virions (EEVs).
IMVs are robust virions and capable of long-term survival in the
environment. In comparison CEVs and EEVs are more labile but
crucial for efﬁcient and timely cell to cell spread of VACV in vivo and
in vitro (Blasco and Moss, 1992; Smith et al., 2003). Alternative
nomenclature refers to IMVs as mature virions, IEVs as wrapped
virions, and CEVs and EEVs as extracellular virions (Moss, 2006).
The intricate cell–virus interactions involved in poxvirus mor-
phogenesis are still incompletely understood. High throughput,
unbiased, RNA interference screens have been used to identify
cellular proteins which are required for poxvirus replication
(Beard et al., 2014; Mercer et al., 2012; Sivan et al., 2013; Teferi
et al., 2013). Two of these screens identiﬁed RAB1A as a strongly
proviral host factor (Beard et al., 2014; Sivan et al., 2013). Only a
small number of individual cellular proteins were identiﬁed in
multiple screens, suggesting these particular proteins play a
crucial role in the virus life cycle and are therefore worthy of
detailed investigation.
RAB1A is a member of the Rab GTPase protein family. This
family contains over 60 human Rab proteins which localise to
speciﬁc intracellular membranes and act as directors and organi-
sers of membrane trafﬁcking including pathways among the ER,
golgi, endosomes, lysosomes, phagosomes and autophagosomes
(Stenmark, 2009). The most well-known function of RAB1A is to
facilitate vesicle trafﬁcking from the endoplasmic reticulum (ER)
to the Golgi. This pathway consists of the ER, the ER–Golgi
intermediate compartment (ERGIC), and the cis face of the Golgi.
Anterograde transport begins at specialised areas of the ER known
as ER exit sites (ERES) which produce and release vesicles coated
in the membrane coat complex COPII. The small GTPase Sar1 is
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essential for the formation of these COPII vesicles (Donaldson and
Jackson, 2011). RAB1A localises predominantly to the ERGIC
membrane and recruits the tethering factor p115 to the COPII
coated vesicles, facilitating the formation of a fusion complex and
thus directing COPII vesicles to the Golgi for delivery of their cargo
(Allan et al., 2000). However, in addition to its function in ER to
Golgi transport, RAB1A is also involved in early Golgi trafﬁcking
(Yamasaki et al., 2009), the motility of early endocytotic vesicles,
early endosome to Golgi trafﬁcking (Mukhopadhyay et al., 2011),
regulation of the actin cytoskeleton (Kicka et al., 2011), recycling of
the integrin protein ITGB1 to the cell surface (Wang et al., 2010)
and autophagy (Winslow et al., 2010). RAB1A is therefore a
multifunctional protein with roles in varied cellular processes.
Previous work has revealed a role for RAB1A in the life cycles of
a number of viruses. RAB1A is required for the trafﬁcking of viral
envelope glycoproteins of HIV (Nachmias et al., 2012) and HSV-1
(Zenner et al., 2011), highlighting the protein's role in maintenance
of a functional Golgi. In contrast, RAB1A plays a direct role in
Hepatitis C virus replication, interacting with the viral protein
NS5A and promoting lipid droplet formation (Nevo-Yassaf et al.,
2012; Sklan et al., 2007). Examination of known RAB1A functions
produces a number of hypotheses for the proviral role of RAB1A in
VACV replication cycle. In an analogous manner to HIV and HSV-1,
RAB1A may be required to maintain Golgi function which, for
poxviruses, is vital for the production of IEVs and therefore CEVs
and EEVs (Ulaeto et al., 1995). However, alternative hypotheses
exist. RAB1A has been shown to be rapidly recruited to plasma-
membrane lipid rafts within 30 min of VACV infection (Schroeder
et al., 2012), suggesting a possible role in virus entry. In support of
this theory, RAB1A regulates the recycling of ITGB1 to the cell
surface (Wang et al., 2010) and this integrin protein has been
shown to facilitate VACV entry (Izmailyan et al., 2012). An alter-
native hypothesis is that RAB1A plays a novel role in VACV
replication. This is the case for another cellular protein concerned
with vesicle trafﬁcking, golgin-97. Golgin-97 is a tethering factor
which facilitates retrograde transport from endosomes back to the
trans-Golgi network (Lieu et al., 2007; Lu et al., 2004). Knockdown
of golgin-97 in VACV infected cells unexpectedly resulted in
disruption of IMV formation and accumulation of immature
virions (Alzhanova and Hruby, 2006, 2007). It is unclear why this
protein, which facilitates a late stage of the vesicle transport
system, should inhibit early stages of VACV morphogenesis.
Given the multiple plausible hypotheses for the role of RAB1A
in VACV replication, we investigated the stage of the viral life cycle
for which RAB1A is required.
Results
RAB1A is a proviral cellular factor in VACV replication
RAB1A was identiﬁed as a strongly proviral cellular protein in
two independent, high-throughput siRNA screens of VACV replica-
tion (Beard et al., 2014; Sivan et al., 2013). To investigate this result
further HeLa cells were mock transfected or transfected either
with a non-targeting negative control siRNA (RSCF) or siRNA
targeting RAB1A. A siRNA SMARTpool containing four different
siRNAs all targeting RAB1A was used to enhance the magnitude
and speciﬁcity of protein knockdown. After 48 h of transfection
cellular proteins were collected and the level of RAB1A protein in
the cell lysates was compared using western blotting. The level of
RAB1A was substantially reduced in cells treated with siRNA
targeting RAB1A (Fig. 1A), conﬁrming the efﬁcacy of the siRNA
knock down. The impact of RAB1A on VACV replication and spread
was then examined using VACV-A5L-EGFP, a VACV strain which
has the A5 viral capsid protein tagged with EGFP, thereby enabling
virus growth to be estimated by measuring ﬂuorescence levels
(Beard et al., 2014; Carter et al., 2003). HeLa cells were mock
transfected or transfected with non-targeting RSCF siRNA (nega-
tive control), siRNA targeting PRK-AB1 (positive control) which is
required for efﬁcient VACV replication (Moser et al., 2010), or the
RAB1A siRNA SMARTpool. In addition, the SMARTpool was decon-
voluted to the four constituent siRNAs and each tested individu-
ally. After 48 h the cells were infected with VACV-A5L-EGFP at a
low MOI of 0.1 and ﬂuorescence measured after a further 48 h,
allowing multiple rounds of virus replication to have occurred
(Fig. 1B). Cells were also examined using light microscopy for
evidence of any cytotoxic effect of the siRNAs with none detected
(data not shown). Fluorescence levels were comparable in the
negative control samples (mock and RSCF transfected), but sig-
niﬁcantly reduced in the wells treated with positive control siRNA
(PRK-AB1), the RAB1A SMARTpool and three of the four deconvo-
luted RAB1A siRNAs.
To assess the effect of RAB1A depletion on viral growth kinetics
a multistep growth curve was carried out using both ﬂuorescence
levels and viral plaque titration to measure virus replication. Cells
were mock transfected or transfected with siRNA targeting the
herpesvirus protein VP16 (negative control) or the RAB1A siRNA
SMARTpool. After 48 h cells were infected with VACV-A5L-EGFP at
an MOI of 0.1 followed by measurement of ﬂuorescence and viral
titres at 12 h intervals. EGFP expression was comparable in the
negative control samples (mock and VP16) but signiﬁcantly lower
at 36 and 48 hpi in cells with reduced levels of RAB1A (Fig. 1C).
Virus titration (Fig. 1D) revealed a statistically signiﬁcant reduction
in the amount of infectious virus at 36 and 48 hpi in cells lacking
RAB1A compared with control cells. Overall, these results sub-
stantiate the previously reported evidence from the high through-
put siRNA screens that RAB1A is required for efﬁcient multicycle
growth of VACV (Beard et al., 2014; Sivan et al., 2013).
RAB1A is required for optimal production of EEVs but not IMVs
In order to determine the stage of the VACV life cycle for which
RAB1A is required we carried out a onestep growth curve measuring
ﬂuorescence levels and viral titres at regular intervals. HeLa cells were
mock transfected or transfected with siRNA targeting either VP16 or
RAB1A, and after 48 h infected with VACV-A5L-EGFP (MOI¼5). In
contrast to the multistep growth curve, EGFP levels in RAB1A, VP16
and mock transfected cells were comparable at all time points in the
onestep growth curve (Fig. 2A). EGFP expression by the VACV-A5L-
EGFP virus is under the control of the A5 promoter which is expressed
both early and late in the viral transcriptional cascade (Yang et al.,
2011). Therefore this suggests that all stages of viral replication up to
and including late gene expression are unaffected by loss of RAB1A.
Titration of the cell associated fraction (which consists almost entirely
of IMVs) revealed comparable virus titres in control and RAB1A siRNA
transfected cells at all time points, in agreement with the uniform
ﬂuorescent results (Fig. 2B).
To examine speciﬁcally the impact of RAB1A on later stages of
VACV replication we titrated the amount of virus present in the
supernatant of cells with normal or reduced amount of RAB1A.
Neutralising antibody to IMVs was added to the supernatant
fraction prior to titration to ensure that only EEVs that had been
released from the cell were titrated. We carried out a onestep
growth curve four times (four biological replicates) and at 24 hpi
identiﬁed an average 0.5 log10 reduction in the amount of virus in
the supernatant fraction from cells in which RAB1A was knocked
down in comparison to control cells (Po0.05) (Fig. 2C), indicating
that fewer EEVs are produced from cells lacking normal levels
of RAB1A.
The number of CEVs and EEVs produced by an infected cell
inﬂuences the size and morphology of the viral plaque, and the
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length of the viral “comet tail” which is formed by secondary
plaques emanating from a primary plaque when liquid overlay is
used (Blasco and Moss, 1991, 1992). We therefore compared viral
plaque size and comet tail length in BS-C-1 cells which had been
transfected with nontargeting siRNA (VP16) or siRNA targeting
RAB1A (Fig. 2D and E). Comet tails were signiﬁcantly shorter and
plaque size was signiﬁcantly smaller in BS-C-1 cells treated with
RAB1A targeting siRNA, supporting the results of the onestep
growth curve described above which revealed a reduction in EEV
production.
As outlined above, the association of RAB1A with lipid rafts and
ITGB1 could suggest a role for this protein in VACV cell entry. We
have previously shown that subtle defects in virus entry can be
detected by delayed early gene expression (Haga et al., 2014). We
therefore compared the production of A46, an early VACV protein
(Stack et al., 2005), in cells with normal and reduced levels of
RAB1A (Fig. 2F). A46 was ﬁrst detected in all samples 4 hpi and
remained present at comparable levels throughout the time
course. We also measured production of the late viral protein D8
(Fig. 2F). This was ﬁrst detected at 8 hpi and, as expected, was
expressed at similar amounts in all treatments at all time points.
These results support the onestep growth curve results which
indicate that all stages of virus replication up to and including the
production of the ﬁrst mature virion form, the IMV, are unaffected
by a reduction in the amount of RAB1A present in the cell, and that
RAB1A is therefore not required for efﬁcient VACV entry.
RAB1A is required for production of IEVs
Given that reduced RAB1A expression did not affect VACV entry
or IMV production, but did demonstrate a substantial negative
effect speciﬁcally on EEV production, we concentrated on the
hypothesis that RAB1A depletion blocks EEV production through
disruption of Golgi function. Our initial question was whether
RAB1A depletion resulted in disruption of the Golgi as expected
(Haas et al., 2007). HeLa cells were transfected with siRNA
targeting RAB1A or VP16 for 48 h before being ﬁxed and permea-
bilised. Cells were then labelled with antibody raised against the
Golgi marker GM130. Focal, perinuclear Golgi labelling could be
clearly identiﬁed in VP16 siRNA transfected cells; however in cells
treated with RAB1A siRNA the ﬂuorescence was reduced and
dispersed (Fig. 3A), consistent with disruption of Golgi due to
impaired RAB1A function.
To identify the point at which EEV production is impacted by
reduced levels of RAB1A, we assessed the number and location of IEV
and CEV particles present in cells in which RAB1A is knocked down.
We repeated the siRNA transfection of HeLa cells, then infected with
VACV-A5L-EGFP for 8 h prior to ﬁxation and permeabilisation. The
Fig. 1. A reduction in RAB1A expression inhibits VACV replication. (A) Western blot image of protein lysates from HeLa cells mock transfected or transfected with non-
targeting siRNA (RSCF) or a siRNA SMARTpool targeting RAB1A, probed with antibody against RAB1A (green) or actin (red), and visualised using the Odysseys Infrared
Imaging System (Li-Cor Biosciences). (B) HeLa cells (seeded on 96 well plates) were mock transfected or transfected in triplicate with non-targeting siRNA (RSCF), or siRNA
targeting PRK-AB1, a RAB1A siRNA SMARTpool (SP), or four individual deconvoluted RAB1A siRNAs (DC1–DC4). After 48 h, cells were infected with VACV-A5L-EGFP at
MOI¼0.1, and after a further 48 h ﬂuorescence levels were measured. Values shown are the mean corrected for background, error bars represent standard error of the mean,
and P values o0.05 are indicated (t-test). (C, D) Multistep growth curves. HeLa cells were mock transfected or transfected with non-targeting siRNA (VP16) or a siRNA
SMARTpool targeting RAB1A for 48 h, then infected with a MOI of 0.1 with either (C) VACV-A5L-GFP and virus levels determined by ﬂuorescence, or (D) VACV and the
amount of infectious virus levels in both the supernatant and cells combined determined by plaque assay on BS-C-1 cells. (C) Means of three technical replicates, error bars
indicating the standard deviation. P values o0.05 are indicated (t-test). The data are representative of three biological replicates. (D) Average and standard error of the mean
(SEM) of ﬁve biological replicates. P values o0.05 are indicated (mixed model analysis).
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cells were then treated with antibody directed against the viral
protein B5, which is found in IEV and CEV but not IMV membranes
(Engelstad et al., 1992). Numerous IMV and IEV/CEV particles were
identiﬁed in VP16 siRNA transfected cells (Fig. 3B, left panels). The
IMVs (green) were mainly aggregated in viral factories in perinuclear
regions, whereas the B5-labelled virions (red) were scattered
throughout the cytoplasm and occasionally visible as CEVs on tips
of actin tails (Fig. 3C). Cells with reduced levels of RAB1A contained
similar amounts of IMVs within punctate perinuclear viral factories;
however very few red labelled virions (IEVs or CEVs) or actin tails
were detected in these cells (Fig. 3B, right panels). Quantiﬁcation of
the number of IEV/CEVs present in multiple VP16 and RAB1A siRNA
transfected cells revealed a signiﬁcant reduction in cells with reduced
levels of RAB1A (Fig. 3D). These ﬁndings are consistent with the
reduction in viral plaque size identiﬁed earlier (Fig. 2E), and suggest a
role for RAB1A in the processing of IMVs to become IEVs.
In order to assess the abundance of IEVs directly, transmission
electron microscopy was carried out on HeLa cells transfected with
siRNA targeting RAB1A or VP16 and then infected with VACV WR
for 8 h. Cytoplasmic viral factories were identiﬁed in cells trans-
fected with either VP16 or RAB1A. These factories contained
numerous IMVs (Fig. 4A and C). Within the cytoplasm of VP16
siRNA transfected cells we also detected multiple IEVs that were
identiﬁable by their additional two membranes creating a well-
deﬁned shadow of irregular thickness around the virion core that
added to the overall width of the particle (Fig. 4D–F). In addition
occasional CEVs were noted on the surface of the VP16 siRNA
transfected cells on the tips of actin tails (Fig. 4B). In contrast to
the various virion forms present in VP16 siRNA transfected cells,
the only mature virions present in RAB1A siRNA transfected cells
were IMVs (Fig. 4C and G). No IEVs or CEVs or actin tails were
identiﬁed in these cells. These results are consistent with the
immunoﬂuorescence results above and indicate that RAB1A loss
does not inﬂuence the production of IMVs but does result in a
reduction in the wrapping of IMVs to become IEVs.
Discussion
RAB1A is known to act as a proviral host factor for a number of
viruses including HIV, HCV and HSV-1. This work reveals that RAB1A
is also required for optimal VACV replication and pinpoints the timing
of RAB1A's mechanism of action to the transition from IMV to IEV.
Onestep growth curves and viral protein expression proﬁles indicated
that, despite its involvement in a wide range of cellular functions that
contribute to VACV replication including integrin localisation and actin
regulation, RAB1A had a negligible effect on early stages of viral
replication with normal amounts of early and late proteins and IMVs
produced in the absence of RAB1A (Fig. 2). The negative effect of
RAB1A depletion on multicycle growth of VACV (Fig. 1A and C) is
therefore likely due entirely to the loss of IEVs, CEVs and EEVs,
emphasising the key role previously established for CEVs and EEVs in
promoting rapid spread of VACV in cell culture (Blasco and Moss,
1991, 1992), reviewed by Smith et al. (2003).
Previous work used pharmacological agents and dominant-
negative inhibitors to show that the wrapping of IMVs to form IEVs
requires a functional ER to Golgi transport system. Cells treated with
brefeldin A, which causes collapse of Golgi membrane stacks, did not
inﬂuence IMV production but did reduce EEV production (Ulaeto
et al., 1995). Similarly, infection of cells with a recombinant VACV
strain expressing a dominant-negative Sar1 protein (which is required
for initiation of ER to Golgi transport) resulted in inhibition of EEV
production but did not affect IMV production (Husain and Moss,
2003). RAB1A plays a crucial role in later stages of ER to Golgi
transport by facilitating the fusion of COPII coated vesicles with the cis
face of the Golgi, and our results show that RAB1A, like Sar1, is
Fig. 2. RAB1A plays a role in EEV but not IMV production. (A–C) Single-step growth curve. HeLa cells were mock transfected or transfected with non-targeting siRNA (VP16)
or a siRNA SMARTpool targeting RAB1A for 48 h then infected with VACV (MOI¼5). Total virus loads were determined at the indicated times by ﬂuorescence (A) or plaque
assay (B, C). (A) Mean value of six technical replicates is shown and error bars represent standard error of the mean. The results are representative of three biological
replicates. Plaque assays of the cellular (B) and supernatant (C) fractions of infected cell cultures were carried out on BS-C-1 cells. The graph shows the average and standard
error or the mean (SEM) of four biological replicates. P values o0.05 are indicated (mixed model analysis). (D) Graph comparing the length of comet tails (n¼10) in BS-C-1
cells transfected with non-targeting VP16 siRNA or a siRNA SMARTpool targeting RAB1A for 48 h then infected with VACV. (E) Graph comparing plaque diameter (n¼10) in
BS-C-1 cells transfected with non-targeting VP16 siRNA or a siRNA SMARTpool targeting RAB1A for 48 h then infected with VACV. (F) HeLa cells were mock transfected
(M) or transfected with non-targeting VP16 siRNA (V) or a siRNA SMARTpool targeting RAB1A (R) for 48 h then infected with VACV at MOI¼5. Whole-cell lysates were
collected at 0, 4, 8, 12, and 24 hpi. Proteins were separated by SDS-PAGE and analysed by immunoblotting with the indicated antibodies using the Odysseys Infrared Imaging
System (Li-Cor Biosciences).
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Fig. 3. RAB1A knock down causes dispersal of the Golgi and a reduction in the number of B5-labelled virions. HeLa cells were transfected with siRNA targeting VP16 or RAB1A for 48 h
then (A) infected with VACV at 5 PFU/cell for 8 h and then ﬁxed and labelled with anti-GM130 antibody which labels the Golgi (green) and DAPI (blue). Images were acquired with a
Zeiss LSM 710 confocal microscope. (B) Cells were transfected as described above then infected with VACV-A5L-EGFP (green) at 5 PFU/cell for 8 h and then ﬁxed and labelled with anti-
B5 antibody (red), phalloidin (orange), and DAPI (blue). Images are maximum intensity projections acquired with the Zeiss LSM 710 confocal microscope. The cell shown in panels on
the left is representative of the population of cells transfected with nontargeting siRNA (VP16). The cell shown in panels on the right is representative of the population of cells
transfected with siRNA targeting RAB1A. (C) Highmagniﬁcation image of the areawithin the white rectangle on image (B), revealing an actin tail with a CEV at the tip (white arrow), as
well as a cluster of IMVs (yellow arrows) and IEV/CEVs on or near the surface of the cell (white arrowheads). (D) IEVs or CEVs (identiﬁed by red B5 staining colocalised with A5-EGFP
signal) present in the cytoplasm or on the surface of cells were counted. A minimum of 10 cells per treatment were counted and the data are expressed as the average number of B5
stained virions per cell. The error bar depicts the standard deviation and P value o0.05 is indicated (t-test).
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required for IEV, CEV and EEV but not IMV production. This is
consistent with ER to Golgi vesicle trafﬁcking being the mechanism
of function of RAB1A in the VACV lifecycle. It also highlights ER to
Golgi transport as a possible target for novel antipoxviral therapies, or
a means by which to modulate poxviral replication.
Investigation of the role of cellular regulators of vesicle trafﬁck-
ing in poxvirus morphogenesis is a powerful tool for dissecting the
complex cell–host interactions required for VACV virion formation.
Further investigations into interactions between poxviruses and
components of the vesicle trafﬁcking system, such as the regula-
tory Rab proteins, are likely to shed further light on poxvirus
morphogenesis and are worthy of further study.
Materials and methods
Cells, viruses and antibodies
African green monkey kidney epithelioid cells (BS-C-1), and
human cervix carcinoma epithelioid cells (HeLa) were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) (Life Technologies)
containing 50 IU/ml penicillin, 50 μg/ml streptomycin (Sigma) and
10% foetal bovine serum (FBS) (Life Technologies). Cells were
incubated at 37 1C in a 5% CO2 incubator. VACV strain Western
Reserve (VACV) and VACV-A5L-EGFP (Carter et al., 2003) were used
in this work. The anti-A46 antibody was a kind gift from Andrew
Bowie (Stack et al., 2005), the anti-D8 antibody a kind gift from
Geoffrey Smith (Parkinson and Smith, 1994). Other antibodies used
were anti-RAB1A (ab97956, Abcam), anti-GM130 (610822, BD Phar-
mingen), and anti-B5 (NR-556, BeiResources).
siRNA knockdown of RAB1A
siRNA transfection was carried out in HeLa cells as described
previously (Beard et al., 2014). RAB1A SMARTpool or deconvoluted
RAB1A siRNAs, PRK AB1, VP16, or RSCF siRNA (Dharmacon/Thermo
Scientiﬁc) were added to a ﬁnal concentration of 25 nM and the
cells were then incubated at 37 1C, 5% CO2 for 48 h before further
experimental steps were carried out. Sequences of siRNAs used were
as follows: RAB1A DC1 – GAACAAUCACCUCCAGUUA, DC2 – CAAU-
CAAGCUUCAAAUAUG, DC3 – GGAAACCAGUGCUAAGAAU, DC4 – CAG-
CAUGAAUCCCGAAUAU; PRK AB1– CAGAAGCCACAAUAACUUU; VP16 –
GGGCGAAGUUGGACUCGUAUU.
Western blotting and growth curves
The methods used were described previously (Haga et al., 2014).
Brieﬂy for single-step (or onestep) growth curves, HeLa cells were
transfected with the siRNA indicated for 48 h before being infected
with VACV at an MOI of 10 for 1 h at 37 1C. The cells were then
washed with medium and incubated for the times indicated. Super-
natants were collected and centrifuged at low speed to remove cell
debris, then incubated with Rb168 antibody (Law and Smith, 2001) for
1 h at 37 1C in order to neutralise IMV particles. The titres of the virus
present in the supernatants were determined by plaque assay on BS-
C-1 cells. The titre of the virus in the cellular fraction was determined
by collecting the cells and subjecting them to three freeze/thaw cycles
and sonication before titering on BS-C-1 cells. Four biological repli-
cates were performed. For the multistep growth curves, HeLa cells
were transfected with the siRNA indicated for 48 h before being
infected at MOI of 0.01 for 1 h at 37 1C. At the times indicated the
supernatant and cellular fraction were combined by scraping the cells
into the supernatant. The combined supernatant and cellular fraction
was then frozen and thawed three times and sonicated before viral
titres were determined by plaque assay on BS-C-1 cells. Five biological
replicates were performed.
Measurement of comet assays and plaque diameter
The technique was adapted from Blasco and Moss (1992). BS-C-1
cell monolayers were transfected with non-targeting siRNA (VP16) or
siRNA targeting RAB1A, as described above. After 48 h the monolayers
were infected with dilutions of VACV-WR. After 1 h at 37 1C, the virus
inoculum was removed, fresh DMEM was added, and the incubation
continued at 37 1C. After a further 5 h the medium was replaced with
DMEM containing 1 μg/ml trypsin. The incubation then proceeded at
37 1C until 72 h postinfection, when monolayers were stained with
crystal violet. Images of comet tails and plaques were taken using a
Zeiss Axiovert 40 CFL inverted microscope and a Canon Powershot
A640 camera. The length of the comet tails and diameter of the viral
plaques were determined using Adobe Photoshop image software.
Confocal microscopy
HeLa cells were seeded onto glass coverslips in a 6-well plate and
incubated for 24 h at 37 1C before transfection with siRNA. After a
further 48 h incubation cells were infected with VACV-A5L-EGFP
(MOI¼5) for 1 h at 37 1C. Inocula were removed and cells overlaid
with 2.5% DMEM. At 8 hpi the media was removed, cells were washed
gently thrice with ice cold PBS, then ﬁxed with 10% neutral buffered
Fig. 4. RAB1A knock down results in reduced IEV presence in a cell. HeLa cells were
transfected with siRNA targeting VP16 or RAB1A for 48 h then infected with VACV
at MOI¼5 for 8 h before being ﬁxed with 4% PFA, 2.5% gluteraldehyde in 0.2M
PIPES and processed for TEM. (A, C) Images of cytoplasmic viral factories containing
multiple IMVs. (B) Image of the surface of a cell with the arrowhead pointing to a
CEV on the cell surface, and arrows pointing to two CEVs on the tips of actin tails.
(D–F) High magniﬁcation images of IEVs within VP16 siRNA transfected cells.
(G) High magniﬁcation image of two IMVs within a RAB1A siRNA transfected cell
for comparison. Scale bars for images A–C¼214 nm, for images D–G¼88 nm.
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formalin. Cells were then washed again thrice with PBS and permea-
bilised for 5 min with 0.01% Triton X-100. The samples were then
incubated for 1 h at RT with antibody directed against B5 (1:500) or
GM130 (1:500), followed by three washes in PBS with 2% FBS. The
coverslips were then incubated for 1h at RT with AlexaFluor con-
jugated anti-rabbit or anti-mouse antibody (Life Technologies) and,
where indicated, AlexaFluor conjugated phalloidin (Life Technologies),
followed by three further washes in PBS. Finally, the coverslips were
mounted with ProLongs Gold with DAPI (Molecular Probes). Images
were acquired using a Zeiss LSM 710 confocal microscope and Zen
2011 software (Zeiss).
Electron microscopy
HeLa cells were seeded onto glass coverslips, tranfected as
described above, incubated for 48 h at 37 1C and then infected
with VACV (MOI¼5). At 8 hpi cells were ﬁxed in 4% PFA, 2.5%
gluteraldehyde in 0.2 M PIPES, and washed in 0.2 M PIPES. Cells
were post-ﬁxed in 1% osmium tetroxide, washed in dH2O, dehy-
drated through graded ethanols into propylene oxide and then
inﬁltrated with Durcupan resin through propylene oxide/Durcu-
pan steps. Cells in Durcupan were then placed in moulds and
baked at 60 1C overnight. Ultra-thin sections (Leica Ultramicro-
tome) were stained with uranyl acetate and lead citrate and
viewed using a JEOL 1200EX transmission electron microscope.
Statistical analysis
Analyses of ﬂuorescence levels in multistep and onestep growth
curves, comet tail length, plaque diameter, and the number of IEV/
CEV in a cell were carried out using a Student's t-test. Log transfor-
mations of the titration data from multistep and onestep growth
curves were analysed using a repeated measures mixed model
(Brown and Prescott, 2006). Each model ﬁtted: treatment, time,
and the treatment time interaction as ﬁxed effects; and replicate,
treatment replicate interaction and replicate time interaction as
random effects. The inclusion of the replicate effects and their
interactions as random allowed variation occurring between the
replicates to be taken into account in the conﬁdence intervals and
the statistical tests used to compare treatments at each time point.
Funding source
The Roslin Institute receives Institute Strategic Grant funding
from the Biotechnology and Biological Sciences Research Council
(BBSRC).
Acknowledgments
The authors thank Paul Digard for assistance in manuscript
preparation and Bob Fleming for imaging assistance.
References
Allan, B.B., Moyer, B.D., Balch, W.E., 2000. Rab1 recruitment of p115 into a cis-
SNARE complex: programming budding COPII vesicles for fusion. Science 289,
444–448.
Alzhanova, D., Hruby, D.E., 2006. A trans-Golgi network resident protein, golgin-97,
accumulates in viral factories and incorporates into virions during poxvirus
infection. J. Virol. 80, 11520–11527.
Alzhanova, D., Hruby, D.E., 2007. A host cell membrane protein, golgin-97, is
essential for poxvirus morphogenesis. Virology 362, 421–427.
Beard, P.M., Grifﬁths, S.J., Gonzalez, O., Haga, I.R., Pechenick Jowers, T., Reynolds, D.K.,
Wildenhaim, J., Tekotte, H., Auer, M., Tyers, M., Ghazal, P., Zimmer, R., Haas, J., 2014.
A loss of function analysis of host factors inﬂuencing vaccinia virus replication by
RNA interference. PLoS One 9 (6), e9831, Jun 5.
Blasco, R., Moss, B., 1991. Extracellular vaccinia virus formation and cell-to-cell
virus transmission are prevented by deletion of the gene encoding the 37,000-
Dalton outer envelope protein. J. Virol. 65, 5910–5920.
Blasco, R., Moss, B., 1992. Role of cell-associated enveloped vaccinia virus in cell-to-
cell spread. J. Virol. 66, 4170–4179.
Brown, H., Prescott, R., 2006. Applied Mixed Models in Medicine. John Wiley & Sons
Ltd., Chichester, United Kingdom.
Carter, G.C., Rodger, G., Murphy, B.J., Law, M., Krauss, O., Hollinshead, M., Smith, G.L.,
2003. Vaccinia virus cores are transported on microtubules. J. Gen. Virol. 84,
2443–2458.
Donaldson, J.G., Jackson, C.L., 2011. ARF family G proteins and their regulators: roles
in membrane transport, development and disease. Nat. Rev. Mol. Cell Biol. 12,
362–375.
Engelstad, M., Howard, S.T., Smith, G.L., 1992. A constitutively expressed vaccinia
gene encodes a 42-kDa glycoprotein related to complement control factors that
forms part of the extracellular virus envelope. Virology 188, 801–810.
Haas, A.K., Yoshimura, S., Stephens, D.J., Preisinger, C., Fuchs, E., Barr, F.A., 2007.
Analysis of GTPase-activating proteins: Rab1 and Rab43 are key Rabs required
to maintain a functional Golgi complex in human cells. J. Cell Sci. 120,
2997–3010.
Haga, I.R., Pechenick Jowers, T., Grifﬁths, S.J., Haas, J., Beard, P.M., 2014. TRAF2
facilitates vaccinia virus replication by promoting rapid virus entry. J. Virol. 88,
3664–3677.
Hiller, G., Weber, K., 1985. Golgi-derived membranes that contain an acylated viral
polypeptide are used for vaccinia virus envelopment. J. Virol. 55, 651–659.
Husain, M., Moss, B., 2003. Evidence against an essential role of COPII-mediated
cargo transport to the endoplasmic reticulum-Golgi intermediate compartment
in the formation of the primary membrane of vaccinia virus. J. Virol. 77,
11754–11766.
Izmailyan, R., Hsao, J.C., Chung, C.S., Chen, C.H., Hsu, P.W., Liao, C.L., Chang, W., 2012.
Integrin beta1 mediates vaccinia virus entry through activation of PI3K/Akt
signaling. J. Virol. 86, 6677–6687.
Kicka, S., Shen, Z., Annesley, S.J., Fisher, P.R., Lee, S., Briggs, S., Firtel, R.A., 2011. The
LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin
cytoskeleton. Mol. Biol. Cell 22, 2198–2211.
Law, M., Smith, G.L., 2001. Antibody neutralization of the extracellular enveloped
form of vaccinia virus. Virology 280, 132–142.
Lieu, Z.Z., Derby, M.C., Teasdale, R.D., Hart, C., Gunn, P., Gleeson, P.A., 2007. The
golgin GCC88 is required for efﬁcient retrograde transport of cargo from the
early endosomes to the trans-Golgi network. Mol. Biol. Cell 18, 4979–4991.
Lu, L., Tai, G., Hong, W., 2004. Autoantigen golgin-97, an effector of Arl1 GTPase,
participates in trafﬁc from the endosome to the trans-Golgi network. Mol. Biol.
Cell 15, 4426–4443.
Mercer, J., Snijder, B., Sacher, R., Burkard, C., Bleck, C.K., Stahlberg, H., Pelkmans, L.,
Helenius, A., 2012. RNAi screening reveals proteasome- and Cullin3-dependent
stages in vaccinia virus infection. Cell Rep. 2, 1036–1047.
Moser, T.S., Jones, R.G., Thompson, C.B., Coyne, C.B., Cherry, S., 2010. A kinome RNAi
screen identiﬁed AMPK as promoting poxvirus entry through the control of
actin dynamics. PLoS Pathog. 6, e1000954.
Moss, B., 2006. Poxvirus entry and membrane fusion. Virology 344, 48–54.
Moss, B., 2007. Poxviridae: the viruses and their replication. In: Knipe, D.M.,
Howley, P.M. (Eds.), Fields Virology, 5 ed. Lippincott Williams & Wilkins,
pp. 2906–2945.
Mukhopadhyay, A., Nieves, E., Che, F.Y., Wang, J., Jin, L., Murray, J.W., Gordon, K.,
Angeletti, R.H., Wolkoff, A.W., 2011. Proteomic analysis of endocytic vesicles:
Rab1a regulates motility of early endocytic vesicles. J. Cell Sci. 124, 765–775.
Nachmias, D., Sklan, E.H., Ehrlich, M., Bacharach, E., 2012. Human immunodeﬁ-
ciency virus type 1 envelope proteins trafﬁc toward virion assembly sites via a
TBC1D20/Rab1-regulated pathway. Retrovirology 9, 7.
Nevo-Yassaf, I., Yaffe, Y., Asher, M., Ravid, O., Eizenberg, S., Henis, Y.I., Nahmias, Y.,
Hirschberg, K., Sklan, E.H., 2012. Role for TBC1D20 and Rab1 in hepatitis C virus
replication via interaction with lipid droplet-bound nonstructural protein 5A.
J. Virol. 86, 6491–6502.
Parkinson, J.E., Smith, G.L., 1994. Vaccinia virus gene A36R encodes a M(r) 43–50 K
protein on the surface of extracellular enveloped virus. Virology 204, 376–390.
Payne, L.G., 1980. Signiﬁcance of extracellular enveloped virus in the in vitro and
in vivo dissemination of vaccinia. J. Gen. Virol. 50, 89–100.
Schroeder, N., Chung, C.S., Chen, C.H., Liao, C.L., Chang, W., 2012. The lipid raft-
associated protein CD98 is required for vaccinia virus endocytosis. J. Virol. 86,
4868–4882.
Sivan, G., Martin, S.E., Myers, T.G., Buehler, E., Szymczyk, K.H., Ormanoglu, P., Moss, B.,
2013. Human genome-wide RNAi screen reveals a role for nuclear pore proteins in
poxvirus morphogenesis. Proc. Natl. Acad. Sci. USA 110, 3519–3524.
Sklan, E.H., Serrano, R.L., Einav, S., Pfeffer, S.R., Lambright, D.G., Glenn, J.S., 2007.
TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus
replication. J. Biol. Chem. 282, 36354–36361.
Smith, G.L., Murphy, B.J., Law, M., 2003. Vaccinia virus motility. Annu. Rev.
Microbiol. 57, 323–342.
Stack, J., Haga, I.R., Schroder, M., Bartlett, N.W., Maloney, G., Reading, P.C., Fitzgerald, K.A.,
Smith, G.L., Bowie, A.G., 2005. Vaccinia virus protein A46R targets multiple Toll-like-
interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201,
1007–1018.
Stenmark, H., 2009. Rab GTPases as coordinators of vesicle trafﬁc. Nat. Rev. Mol. Cell
Biol. 10, 513–525.
T. Pechenick Jowers et al. / Virology 475 (2015) 66–7372
Teferi, W.M., Dodd, K., Maranchuk, R., Favis, N., Evans, D.H., 2013. A whole-genome
RNA interference screen for human cell factors affecting myxoma virus
replication. J. Virol. 87, 4623–4641.
Ulaeto, D., Grosenbach, D., Hruby, D.E., 1995. Brefeldin A inhibits vaccinia virus
envelopment but does not prevent normal processing and localization of the
putative envelopment receptor P37. J. Gen. Virol. 76 (Pt 1), 103–111.
Wang, C., Yoo, Y., Fan, H., Kim, E., Guan, K.L., Guan, J.L., 2010. Regulation of Integrin
beta 1 recycling to lipid rafts by Rab1a to promote cell migration. J. Biol. Chem.
285, 29398–29405.
Winslow, A.R., Chen, C.W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A.,
Lichtenberg, M., Menzies, F.M., Ravikumar, B., Imarisio, S., Brown, S., O'Kane, C.J.,
Rubinsztein, D.C., 2010. alpha-Synuclein impairs macroautophagy: implications for
Parkinson's disease. J. Cell Biol. 190, 1023–1037.
Yamasaki, A., Menon, S., Yu, S., Barrowman, J., Meerloo, T., Oorschot, V.,
Klumperman, J., Satoh, A., Ferro-Novick, S., 2009. mTrs130 is a component of
a mammalian TRAPPII complex, a Rab1 GEF that binds to COPI-coated vesicles.
Mol. Biol. Cell 20, 4205–4215.
Yang, Z., Reynolds, S.E., Martens, C.A., Bruno, D.P., Porcella, S.F., Moss, B., 2011.
Expression proﬁling of the intermediate and late stages of poxvirus replication.
J. Virol. 85, 9899–9908.
Zenner, H.L., Yoshimura, S., Barr, F.A., Crump, C.M., 2011. Analysis of Rab GTPase-
activating proteins indicates that Rab1a/b and Rab43 are important for herpes
simplex virus 1 secondary envelopment. J. Virol. 85, 8012–8021.
T. Pechenick Jowers et al. / Virology 475 (2015) 66–73 73
